JNJ

NYSEEQUITY

Johnson & Johnson

$225.33-5.47-2.37%

Price History

Overlays:

RSI (14)

Relative Strength Index. > 70 overbought, < 30 oversold.

MACD (12, 26, 9)

Trend & momentum. Histogram = MACD − Signal.

Volume

Trading volume colored by daily price direction

News Sentiment

+0.12

Positive4 (40%)

Neutral6 (60%)

Negative0 (0%)

Based on 10 headlines analyzed via VADER-style financial lexicon.

Latest News

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
PR Newswire·13h agoPOSITIVE+0.36
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
PR Newswire·13h agoNEUTRAL+0.00
How to Build $12,500 a Month in Dividend Income From a $2.8 Million Portfolio Without Touching the Aggressive Tier
24/7 Wall St.·7h agoPOSITIVE+0.27
Nanobiotix Equity Raise Backs JNJ-1900 Progress And Volatile Share Rally
Simply Wall St.·1d agoPOSITIVE+0.27
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm
GlobeNewswire·12h agoNEUTRAL+0.00
JNJ Reports Promising Survival Data From CHRYSALIS-2 Lung Cancer Study
Stocktwits·2d agoNEUTRAL+0.00
Johnson & Johnson (JNJ) Stock Slides as Market Rises: Facts to Know Before You Trade
Zacks·2d agoPOSITIVE+0.34
The Two Bucket Income Portfolio That Pays $5,000 a Month Plus a Cash Reserve to Survive 2008 Style Drawdowns
24/7 Wall St.·1d agoNEUTRAL+0.00
How to Recession-Proof Your Retirement Income Before Summer 2026
Motley Fool·1d agoNEUTRAL+0.00
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
PR Newswire·2d agoNEUTRAL+0.00

Key Statistics

Open: $231.23
Prev Close: $230.80
Day High: $231.48
Day Low: $224.59
52W High: $251.71
52W Low: $149.04
Volume: 6.19M
Avg Volume: 7.7M
Market Cap: 542.42B
P/E (TTM): 26.11
Forward P/E: 17.72
EPS (TTM): $8.63
Div Yield: +238.00%

Trading Signal

HOLD

Neutral bias

Confidence

20%

Rationale

•Golden cross: 50-day SMA above 200-day SMA (bullish trend).
•Price is below the 20-day SMA (short-term bearish).
•RSI 42.8 is in the neutral zone.
•MACD histogram is positive.
•Ensemble forecast: 0.22% expected over 7 sessions.

Educational use only. Not investment advice. Past performance is not indicative of future results.

ML Forecast

7-day horizon

Ensemble of linear regression, drift, and Holt's exponential smoothing.

Target Price

$225.83

Expected Return

+0.22%

Model Outputs

Linear Regression$229.93

Drift Method$225.91

Holt Smoothing$224.04

RMSE

7.58

MAE

6.13

R²

0.103

JNJ

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm

How to Build $12,500 a Month in Dividend Income From a $2.8 Million Portfolio Without Touching the Aggressive Tier

Nanobiotix Equity Raise Backs JNJ-1900 Progress And Volatile Share Rally

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm

JNJ Reports Promising Survival Data From CHRYSALIS-2 Lung Cancer Study

Johnson & Johnson (JNJ) Stock Slides as Market Rises: Facts to Know Before You Trade

The Two Bucket Income Portfolio That Pays $5,000 a Month Plus a Cash Reserve to Survive 2008 Style Drawdowns

How to Recession-Proof Your Retirement Income Before Summer 2026

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

Rationale

Model Outputs

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm

How to Build $12,500 a Month in Dividend Income From a $2.8 Million Portfolio Without Touching the Aggressive Tier

Nanobiotix Equity Raise Backs JNJ-1900 Progress And Volatile Share Rally

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm

JNJ Reports Promising Survival Data From CHRYSALIS-2 Lung Cancer Study

Johnson & Johnson (JNJ) Stock Slides as Market Rises: Facts to Know Before You Trade

The Two Bucket Income Portfolio That Pays $5,000 a Month Plus a Cash Reserve to Survive 2008 Style Drawdowns

How to Recession-Proof Your Retirement Income Before Summer 2026

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

Rationale

Model Outputs